We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMDX Partners With Mercedes-Benz to Launch Organ Transport Network
Read MoreHide Full Article
Key Takeaways
TMDX and Mercedes-Benz will deploy vehicles for Italy's first organ transport network.
The initiative supports the use of TMDX's Organ Care System across four National OCS Program hubs.
TMDX hubs in Milan, Rome, Padua, and Bari will launch by 2025 with full logistical support.
TransMedics (TMDX - Free Report) has announced a strategic collaboration with Mercedes-Benz to launch Italy’s first dedicated organ transplantation ground transportation network. The initiative will deploy purpose-built Mercedes-Benz V-Class vehicles across four National OCS Program (NOP) hubs, supporting the use of TransMedics’ Organ Care System (OCS) technology.
This development underscores TMDX’s effort to replicate its successful U.S. logistics model in Europe and enhance its global transplant ecosystem. By integrating advanced vehicles with its OCS platform, TransMedics aims to improve donor organ utilization and expand patient access to life-saving transplants across Italy.
Likely Trend of TMDX Stock Following the News
Following the announcement, the company's shares lost 2.6% at yesterday’s market closing. Shares have rallied 88.4% in the year-to-date period against the industry’s 11.6% decline. The S&P 500 has gained 14.2% in the same time frame.
This partnership positions TMDX to extend its U.S. National OCS Program model into Europe, creating a scalable logistics and service network that complements its OCS platform. By easing adoption for hospitals and ensuring reliable organ transport, TMDX can drive higher procedure volumes, boost recurring disposable sales, and build sticky service revenues. The collaboration also enhances brand credibility and lays the groundwork for broader European expansion, thereby strengthening long-term growth and creating a competitive moat.
Meanwhile, TMDX currently has a market capitalization of $4.11 billion.
Image Source: Zacks Investment Research
More on the Partnership News
The strategic collaboration with Mercedes-Benz supports TransMedics’ broader commercial strategy to replicate its successful U.S. NOP in Europe by creating a dedicated air and ground logistics network integrated with its OCS perfusion platform and clinical services. This initiative is expected to serve as the foundation for a broader, multi-country European transplant logistics network aimed at expanding donor organ access and utilization. As part of the agreement, TransMedics will deploy and operate a fleet of modern Mercedes-Benz V-Class vehicles across four major Italian NOP hubs located in Milan, Rome, Padua and Bari. These vehicles are engineered with advanced safety features that meet the strict handling requirements of transplant logistics, ensuring secure transport for donor organs, physicians, and equipment.
The first Italian NOP hubs are targeted to launch before the end of 2025. Each hub will be equipped with OCS Lung, Heart, and Liver Systems and operated by experienced clinical perfusionists. TransMedics will provide 24/7 technological, clinical, and logistical support to transplant centers, procurement organizations, and surgical teams to increase donor organ utilization across Italy. To oversee operations, the Italian National Command Center will be based at TransMedics’ NOP hub in Santa Giulia, Milan. This integrated approach positions TransMedics to deliver consistent, end-to-end transplant support services while enhancing the efficiency and reliability of the organ transplantation ecosystem.
More on the TMDX’s OCS Platform and National OCS Program
TransMedics’ OCS is the only FDA-approved, portable, multi-organ warm perfusion platform that preserves donor lungs, hearts, and livers in near-physiologic conditions. By maintaining organs with warm, oxygenated, nutrient-enriched blood, the OCS enables real-time optimization and viability assessment, increasing utilization rates. The company’s NOP builds on this by offering a turnkey service that combines OCS technology with trained procurement specialists, clinical teams and a dedicated air and ground logistics network, streamlining organ delivery and expanding access to transplants.
The combined OCS and NOP model has translated into strong operational and financial growth. In second-quarter 2025, transplant logistics revenues rose 56% year over year to $29.8 million, with a sequential gain of 14%. The NOP’s proprietary aviation fleet, now at 21 aircraft and set to expand to 22 by year-end, supported 79% of missions requiring air transport. Since its launch, the program has facilitated nearly 7,500 U.S. transplants and contributed to 12% of national heart and liver transplant growth in 2023. By extending organ viability and enabling daytime procedures, OCS and NOP are driving higher transplant volumes, improved cost efficiency, and recurring revenue growth.
TMDX’s Zacks Rank & Stocks to Consider
TMDX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TMDX Partners With Mercedes-Benz to Launch Organ Transport Network
Key Takeaways
TransMedics (TMDX - Free Report) has announced a strategic collaboration with Mercedes-Benz to launch Italy’s first dedicated organ transplantation ground transportation network. The initiative will deploy purpose-built Mercedes-Benz V-Class vehicles across four National OCS Program (NOP) hubs, supporting the use of TransMedics’ Organ Care System (OCS) technology.
This development underscores TMDX’s effort to replicate its successful U.S. logistics model in Europe and enhance its global transplant ecosystem. By integrating advanced vehicles with its OCS platform, TransMedics aims to improve donor organ utilization and expand patient access to life-saving transplants across Italy.
Likely Trend of TMDX Stock Following the News
Following the announcement, the company's shares lost 2.6% at yesterday’s market closing. Shares have rallied 88.4% in the year-to-date period against the industry’s 11.6% decline. The S&P 500 has gained 14.2% in the same time frame.
This partnership positions TMDX to extend its U.S. National OCS Program model into Europe, creating a scalable logistics and service network that complements its OCS platform. By easing adoption for hospitals and ensuring reliable organ transport, TMDX can drive higher procedure volumes, boost recurring disposable sales, and build sticky service revenues. The collaboration also enhances brand credibility and lays the groundwork for broader European expansion, thereby strengthening long-term growth and creating a competitive moat.
Meanwhile, TMDX currently has a market capitalization of $4.11 billion.
Image Source: Zacks Investment Research
More on the Partnership News
The strategic collaboration with Mercedes-Benz supports TransMedics’ broader commercial strategy to replicate its successful U.S. NOP in Europe by creating a dedicated air and ground logistics network integrated with its OCS perfusion platform and clinical services. This initiative is expected to serve as the foundation for a broader, multi-country European transplant logistics network aimed at expanding donor organ access and utilization. As part of the agreement, TransMedics will deploy and operate a fleet of modern Mercedes-Benz V-Class vehicles across four major Italian NOP hubs located in Milan, Rome, Padua and Bari. These vehicles are engineered with advanced safety features that meet the strict handling requirements of transplant logistics, ensuring secure transport for donor organs, physicians, and equipment.
The first Italian NOP hubs are targeted to launch before the end of 2025. Each hub will be equipped with OCS Lung, Heart, and Liver Systems and operated by experienced clinical perfusionists. TransMedics will provide 24/7 technological, clinical, and logistical support to transplant centers, procurement organizations, and surgical teams to increase donor organ utilization across Italy. To oversee operations, the Italian National Command Center will be based at TransMedics’ NOP hub in Santa Giulia, Milan. This integrated approach positions TransMedics to deliver consistent, end-to-end transplant support services while enhancing the efficiency and reliability of the organ transplantation ecosystem.
More on the TMDX’s OCS Platform and National OCS Program
TransMedics’ OCS is the only FDA-approved, portable, multi-organ warm perfusion platform that preserves donor lungs, hearts, and livers in near-physiologic conditions. By maintaining organs with warm, oxygenated, nutrient-enriched blood, the OCS enables real-time optimization and viability assessment, increasing utilization rates. The company’s NOP builds on this by offering a turnkey service that combines OCS technology with trained procurement specialists, clinical teams and a dedicated air and ground logistics network, streamlining organ delivery and expanding access to transplants.
The combined OCS and NOP model has translated into strong operational and financial growth. In second-quarter 2025, transplant logistics revenues rose 56% year over year to $29.8 million, with a sequential gain of 14%. The NOP’s proprietary aviation fleet, now at 21 aircraft and set to expand to 22 by year-end, supported 79% of missions requiring air transport. Since its launch, the program has facilitated nearly 7,500 U.S. transplants and contributed to 12% of national heart and liver transplant growth in 2023. By extending organ viability and enabling daytime procedures, OCS and NOP are driving higher transplant volumes, improved cost efficiency, and recurring revenue growth.
TMDX’s Zacks Rank & Stocks to Consider
TMDX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.